Japan has developed a vaccine to prevent stroke

Japanese scientists have successfully prepared the S100A9 vaccine to prevent stroke and cardiovascular diseases that do not cause autoimmune reactions, do not increase the risk of bleeding, bring convenience to patients and help save many lives.

According to Hi-news, clot formation is the cause of various diseases (and often fatal). Of course, there are currently medications to treat blood clots, but continuous use causes very unpleasant consequences to develop bleeding.

S100A9 vaccine has the same effect as anticoagulant, but has a long-term effect.

A vaccine developed by scientists at Osaka University (Japan) can help solve the problem. The vaccine can work not only as a preventive measure, but also as a means to protect against recurrence.

This new vaccine is called S100A9 and has been successfully tested several times on mice. Turns out, S100A9 protected against blood clots continuously for more than 2 months from the time of vaccination.

In addition, vaccines do not cause autoimmune reactions and do not increase the risk of bleeding. According to Dr. Hironori Nakagami, one of the authors of the study, such a long duration of action is really a breakthrough because: 'many stroke patients need to take medication every day, but sometimes they forget or tired of doing it. Thus, it will facilitate the recurrence of stroke. Our vaccine helps overcome that situation. '

In experiments, the S100A9 vaccine was compared with clopidogrel, one of the most common drugs to prevent thrombosis. Turns out, the S100A9 vaccine is as effective as anticoagulant. But scientists are also cautious about the future of their development.

Scientists continue to study in the hope of conducting full clinical trials. Because it is important to understand that between humans and lab rats there are many differences in body activity.